Inclusion Criteria:

• ≥ 30 years of age.
• Either gender.
• Any self-declared ethnicity-race.
• Open-angle with one of the following:
  • Untreated OHT ≥ 21mmHg;
  • Treated OHT with history of IOP ≥ 21 mmHg on 2 prior clinic visits or IOP ≥ 21 mmHg at screening;
  • Mild-to-moderate stage open-angle glaucoma based on history of untreated IOP ≥ 21 mmHg.
• Reliable Humphrey visual field test result within previous 1 year.
• Open on gonioscopy within previous 1 year.
• At least one eye must be phakic.
• Able to cooperate for aqueous humor dynamic procedures.
• Able to participate on site over the multi-visit study period.
• Contact lenses must be removed before topical fluorescein instillation and remain out until study testing the following day is completed.
• Contact lenses must be removed for the entire duration of the study visits.
• All study medication must be used without contact lenses in the eyes.

Exclusion Criteria:

• Women who are pregnant or breastfeeding.
• IOP ≥ 38 in study eye(s) or at discretion of the clinician.
• Refusal to remove contact lenses.
• Advanced visual field loss (MD ≤ -16 dB) or threat to fixation in study eye(s) or at discretion of the clinician.
• Study eye(s) with CCT < 480 microns or > than 620 microns.
• Study eye(s) with any sign of Fuchs cornea dystrophy as noted clinically with guttae and corneal edema.
• Narrow angle of ≤ Shaffer grade 2 for 180o, peripheral synechiae, or peripheral iridotomy in either eye.
• History of acute angle closure crisis in either eye.
• History of glaucoma incisional surgery (e.g., trabeculectomy, glaucoma drainage implant, Xen gel stent) in study eye(s).
• History of minimally invasive glaucoma surgery (MIGS, e.g., angle surgery, Cypass) in study eye(s).
• History of any cycloablation surgery (e.g., micropulse or diode transcleral or endoscopic cyclophotocoagulation) in study eye(s).
• Study eye cannot have history of any past SLT or ALT glaucoma laser treatments.
• Study eye(s) cannot have any history of refractive surgery.
• Study eye(s) cannot have any history of herpetic infection of the cornea.
• Study eye(s) cannot have chronic or recurrent inflammatory eye disease.
• Study eye(s) cannot have ocular trauma within the past 6 months, other than uncomplicated cornea abrasion.
• Study eye(s) cannot have ocular infection in the past 3 months.
• Study eye(s) cannot have clinically significant retinal disease that includes proliferative diabetic retinopathy, vein occlusion, cystoid macular edema, wet age-related macular degeneration.
• History of intraocular or peri-ocular injections in study eye(s) within 3 months.
• History of oral steroid use within 30 days of screening Visit 1.
• Any abnormality preventing reliable fluorophotometry (e.g., corneal scarring or severe dry eye with fluorescein staining).
• Serious hypersensitivity to any components of study medications or risk from treatment (e.g., sulfa drug allergy, bradycardia, severe asthma, or emphysema).
• Participants must be on minimum 30-day stable regimen prior to Visit 1 for a systemic medication that may affect IOP (i.e., sympathomimetics, beta-blockers, alpha-adrenergic agonists and blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, etc.).  Any change of such medication during the study will result in exclusion.
• Prohibited meds during study: cannabis products, brimonidine 0.025% (Lumify), bimatoprost 0.03% for eyelash growth (Latisse), topical ocular and peri-ocular steroids, oral steroids.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 10/17/22. Questions regarding updates should be directed to the study team contact.